Johnson & Johnson has informed the EU that it is facing supply problems for its vaccine, which is likely to be officially approved on Thursday. It may not be possible to deliver the targeted 55 million doses by the end of June. This threatens a new setback for the vaccination campaign.
–
On Thursday, Johnson & Johnson expects European approval for its vaccine, which is partly developed by subsidiary Janssen in Beerse. The chance of a green light is very high: the Americans approved …
– .
